Room 1 — Controller Room 1

진행 중: —
--:--

세션 목록 (14개)

15:20~16:401
Shifting paradigms in geriatric diabetes care
종료
1
유성훈 한양의대 내과 15:20-15:40
Personalized goal setting and prescription transitions; a new standard in elderly diabetes management
2
윤재승 가톨릭의대 내과 15:40-16:00
Diabetes management transformed by telemedicine and digital health
3
배재현 한림의대 내과 16:00-16:20
Conservative approach to diabetes in elderly patients with terminal illness or nursing care
16:50~17:501
Diabetic neuropathy, pathogenic mechanism, treatment Translational frontiers in diabetic neuropathy: from pathogenic mechanisms to next-generation therapies
종료
1
오태정 서울의대 내과 16:50-17:05
The role of neuroinflammation in driving diabetic neuropathy progression
2
김지민 충남의대 내과 17:05-17:20
Integration of corneal confocal microscopy (CCM) and blood-based biomarkers for early detection and phenotyping of diabetic neuropathies
3
김은숙 가톨릭의대 내과 17:20-17:35
Emerging disease-modifying and symptomatic treatments for diabetic neuropathy: a focus on novel molecular targets and neuromodulation
08:00~08:152
Breakfast symposium 1 Tailored antiplatelet therapy for peripheral artery disease patients with diabetes mellitus
종료
1
문신제 한양의대 내과 08:00-08:15
Tailored antiplatelet therapy for peripheral artery disease patients with diabetes mellitus
08:15~08:302
Breakfast symposium 3 Hypertension treatment in diabetes patients from guidelines to clinical practice
종료
1
양여리 가톨릭의대 내과 08:15-08:30
Hypertension treatment in diabetes patients from guidelines to clinical practice
09:00~10:202
Remaining challenges in metabolic care Unresolved challenges in modern metabolic therapies
종료
1
정창희 울산의대 내과 09:00-09:20
Body composition changes with NUSH-based therapy: benefits, concerns, and unmet questions
2
손장원 가톨릭의대 내과 09:20-09:40
Life after NUSH-based therapy: understanding weight regain and strategies for sustained obesity control
3
최종한 건국의대 내과 09:40-10:00
Safety profile of SGLT2 inhibitors: beyond established risks to emerging concerns
12:20~12:352
Luncheon symposium 1 Early metabolic intervention with twincretin–based therapy: clinical importance and implications
종료
1
Tamer Coskun Eli Lilly and Company 12:20-12:35
Early metabolic intervention with twincretin–based therapy: clinical importance and implications
12:35~12:502
Luncheon symposium 5 Anchoring early CKM care: EMPA FIT vs Metformin in treatment-naïve T2D
종료
1
임수 서울의대 내과 12:35-12:50
Anchoring early CKM care: EMPA FIT vs Metformin in treatment-naïve T2D
16:30~17:502
Year in review and perspective Recent advances in human adipose tissue research
종료
1
최성희 서울의대 내과 16:30-17:10
Recent advances in human adipose tissue research
2
김재범 서울대 생명과학부 17:10-17:50
Characterization of different adipose depots: white, beige and brown fat
08:00~08:153
Breakfast Symposium 5 Combination therapy with sulfonylurea and an SGLT2 inhibitor is an effective treatment strategy for type 2 diabetes
종료
1
이민영 연세의대 내과 08:00-08:15
Combination therapy with sulfonylurea and an SGLT2 inhibitor is an effective treatment strategy for type 2 diabetes
08:15~08:303
Breakfast symposium 7 Clinical value of continuous glucose monitoring: physician-led glycemic pattern analysis
종료
1
유승현 가톨릭관동의대 내과 08:15-08:30
Clinical value of continuous glucose monitoring: physician-led glycemic pattern analysis
09:00~10:203
Diabetic kidney disease (Debate) Rethinking treatment strategy in diabetic kidney disease (debate)
종료
1
노정현 인제의대 내과 09:00-09:20
All at once
2
김난희 고려의대 내과 09:20-09:40
One by one
12:20~12:353
Luncheon symposium 8 The standard of Korean diabetes care_why K-evidence matters
종료
1
김경수 차의과학대 내과 12:20-12:35
The standard of Korean diabetes care_why K-evidence matters
12:35~12:503
Luncheon symposium 12 Importance of timely insulin initiation: optimizing glycemic control with 2nd generation basal insulin following GLP-1 RA treatment
종료
1
이은영 가톨릭의대 내과 12:35-12:50
Importance of timely insulin initiation: optimizing glycemic control with 2nd generation basal insulin following GLP-1 RA treatment
14:00~15:203
The evolution of metabolic management Reviewing the clinical significance of local evidence and the advancement of novel therapeutic strategies for metabolic disorders
종료
1
박정환 한양의대 내과 14:00-14:25
The standard of Korean diabetes care: why K-evidence matters
2
김부경 고신의대 내과 14:25-14:50
Why prodrug for dapagliflozin? - phase 4 evidence on non-inferiority and clinical outcomes
3
채유나 동아ST 14:50-15:15
Clinical development of two metabolic therapeutic candidates: vanoglipel for MASH and DA-1726 for obesity